多中心试验中纳入随机中心效应的设计与分析
该研究通过再分析CRASH-2试验(20,127例创伤患者,271个中心,40个国家)数据,探讨多中心试验中中心变异对设计与分析的影响。结果显示,4周死亡风险在国家间和中心间存在显著变异,但治疗效应在国家间和中心间无差异,调整中心和国家变异后平均治疗效应未改变。研究强调应区分结局的基线变异与治疗效应变异,并建议按中心分层随机化及在分析中纳入随机截距。
要点
- 多中心试验中结局的基线变异常见,但治疗效应变异不常见。
- 按中心分层随机化可克服许多统计问题。
- 分析中纳入随机截距可能提高效能并减少均值与标准误估计的偏倚。
核心结论
- 应区分结局的基线变异与治疗效应变异,前者常见而后者不常见。
- 按中心分层随机化可克服许多统计问题。
- 分析中纳入随机截距可能提高效能并减少均值与标准误估计的偏倚。
研究设计与样本
- 对CRASH-2试验数据的再分析。
- CRASH-2随机分配20,127例创伤患者至单剂氨甲环酸或相同安慰剂,覆盖271个中心、40个国家。
- 主要结局为4周全因死亡。
- 数据具有层次结构:患者嵌套于医院,医院嵌套于国家。
- 在logistic回归模型中将治疗效应及患者和中心水平基线协变量作为固定效应,并纳入随机效应评估国家间及国家内中心间的变异。
主要发现
- CRASH-2中4周死亡在国家间和国家内中心间存在显著变异。
- 治疗效应在国家间和中心间无差异。
- 调整中心和国家变异后平均治疗效应未改变。
临床怎么用
- 在多中心试验设计中考虑按中心分层随机化。
- 在分析中可纳入随机截距以考虑中心变异。
- 需区分结局基线变异与治疗效应变异,避免不必要的治疗效应异质性假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In large multicentre trials in diverse settings, there is uncertainty about the need to adjust for centre variation in design and analysis. A key distinction is the difference between variation in outcome (independent of treatment) and variation in treatment effect. Through re-analysis of the CRASH-2 trial (2010), this study clarifies when and how to use multi-level models for multicentre studies with binary outcomes. METHODS: CRASH-2 randomised 20,127 trauma patients across 271 centres and 40 countries to either single-dose tranexamic acid or identical placebo, with all-cause death at 4 weeks the primary outcome. The trial data had a hierarchical structure, with patients nested in hospitals which in turn are nested within countries. Reanalysis of CRASH-2 trial data assessed treatment effect and both patient and centre level baseline covariates as fixed effects in logistic regression models. Random effects were included to assess where there was variation between countries, and between centres within countries, both in underlying risk of death and in treatment effect. RESULTS: In CRASH-2, there was significant variation between countries and between centres in death at 4 weeks, but absolutely no differences between countries or centres in the effect of treatment. Average treatment effect was not altered after accounting for centre and country variation in this study. CONCLUSIONS: It is important to distinguish between underlying variation in outcomes and variation in treatment effects; the former is common but the latter is not. Stratifying randomisation by centre overcomes many statistical problems and including random intercepts in analysis may increase power and decrease bias in mean and standard error estimates. TRIAL REGISTRATION: Current Controlled Trials ISRCTN86750102 , ClinicalTrials.gov NCT00375258 , and South African Clinical Trial Register DOH-27-0607-1919.
引用
- Edgar K, Roberts I, Sharples L, et al. Including random centre effects in design, analysis and presentation of multi-centre trials. Trials. 2021. PMID: 34022937. doi:10.1186/s13063-021-05266-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。